1. Home >
  2. Companies >
  3. Public >
  4. Life Science >
  5. United States >
  6. Texas >
  7. Lexicon Pharmaceuticals >
  8. M&A

Lexicon Pharmaceuticals Mergers & Acquisitions

Lexicon Pharmaceuticals M&A Summary

Lexicon Pharmaceuticals has acquired 1 company. It has also divested 1 asset.

Lexicon Pharmaceuticals’ largest acquisition to date was in 2010, when it acquired Symphony Icon for $90M. It’s largest disclosed sale occurred in 2020, when it sold Lexicon Pharmaceuticals - XERMELO to TerSera Therapeutics for $159M. Lexicon Pharmaceuticals has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).

M&A Summary

  • M&A Total Activity2
    • M&A Buy Activity1
    • M&A Sell Activity1
  • Total Sectors Invested 1
  • Total Countries Invested 1
  • M&A Buy/Sell Connections 1

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard 11th Floor,
The Woodlands, Texas 77381
United States,
(281) 863-3000
www.lexpharma.com

All (2) Buy (1) Sell (1)
Date Target Value
$mlns 		Transaction Type Acquirer Seller SRC
Link
2020-07-30 Lexicon Pharmaceuticals, Inc. - XERMELO · Life Science
The Woodlands, Texas · www.xermelo.com

Lexicon Pharmaceuticals's XERMELO is an approved oral therapy for carcinoid syndrome diarrhea. It targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells. XERMELO is approved in the United States, the European Union, and certain additional countries for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Carcinoid syndrome is a rare condition that occurs in patients living with mNETs and is characterized by frequent and debilitating diarrhea. XERMELO targets the overproduction of serotonin inside mNET cells, providing an additional treatment option for patients suffering from carcinoid syndrome diarrhea.

159 Divestiture

TerSera Therapeutics

Lexicon Pharmaceuticals


Try Mergr Free — See This and 220,573+
Other Company and Investor Profiles Today

Try free. Full access. Cancel anytime.

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
Try Free

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.8K Private Equity Firms
  • 214K M&A Transactions
  • 216K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 83K M&A Contacts
    (PE and M&A Advisors)

What next?

Try Free

Full access to Mergr's investor, acquirer, and transaction data starts here.

Mergr

Solution for

Product

Company

Legal